Infection Clinical Trial
— MEDIASTAPHOfficial title:
Immunological and Bacteriological Approaches to the Development of Postoperative Mediastinitis With Staphylococcus Aureus
NCT number | NCT03262558 |
Other study ID # | 35RC16_9886 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 4, 2016 |
Est. completion date | September 29, 2019 |
Verified date | December 2022 |
Source | Rennes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Cardiac surgery with extracorporeal circulation (ECC) yields a deep immune system dysfunction that exposes patients to postoperative infectious complications. Among these, post-operative mediastinitis with Staphylococcus aureus (SA) generates significant morbidity and mortality. Two radically different approaches have been proposed in recent years to reduce the incidence of this complication. A first approach has attempted, without real success, to decrease postoperative immunosuppression. The second, more efficient, consisted of screening and preoperatively treating patients colonized with SA. However, although its incidence has decreased, postoperative mediastinitis remains a terrible nosocomial infection. The authors believe that a thorough analysis of the immunological changes induced by cardiac surgery will initiate active therapeutics to reduce the post-operative immunosuppression phase, thereby decreasing the risk of nosocomial infections. In addition, a study of the interactions between the operated (host) and staphylococcus aureus (pathogenic) immune systems will provide a better understanding of the mechanisms that expose patients to this bacterium.
Status | Completed |
Enrollment | 27 |
Est. completion date | September 29, 2019 |
Est. primary completion date | July 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria - Patients over 18 years of age - Patients who require cardiac surgery (valvular and / or coronary) with extracorporeal circulation. Non inclusion criteria - Chronic respiratory diseases, - Preoperative left ventricular dysfunction (LVEF <50%), - Immunosuppression (HIV infection, systemic corticosteroid therapy, history of cancer in the year before surgery), - Persons subject to legal protection (safeguard of justice, curatorship, guardianship), - Persons deprived of liberty. |
Country | Name | City | State |
---|---|---|---|
France | Rennes Hospital University | Rennes |
Lead Sponsor | Collaborator |
---|---|
Rennes University Hospital |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Variation of plasma IDO activity | IDO activity is evaluated by the Kynurenin / Tryptophan ratio before and after ECC.
Enzymatic activities will be measured by high performance liquid chromatography (HPLC) on pre- and post-operative blood tests |
Baseline and the morning following surgery | |
Secondary | Variation of phagocytosis capacity of PMNs | Comparison before and after ECC | Baseline and the morning following surgery | |
Secondary | Variation of bactericidal capacity of PMNs | Comparison before and after ECC | Baseline and the morning following surgery | |
Secondary | Variation of phagocytosis capacity of macrophages | Comparison before and after ECC | Baseline and the morning following surgery | |
Secondary | Variation of bactericidal capacity of macrophages | Comparison before and after ECC | Baseline and the morning following surgery | |
Secondary | Effect of an inhibitor of IDO on phagocytosis capacities of PMNs | The day following surgery | ||
Secondary | Effect of an inhibitor of IDO on bactericidal capacities of PMNs | The day following surgery | ||
Secondary | Effect of an inhibitor of IDO on phagocytosis capacities of macrophages | The day following surgery | ||
Secondary | Effect of an inhibitor of IDO on bactericidal capacities of macrophages | The day following surgery | ||
Secondary | Quantification of lymphocytic apoptosis before and after the ECC | Quantification of apoptosis by flow cytometry | Baseline and the morning following surgery | |
Secondary | Quantification of lymphocytic apoptosis in the presence of an inhibitor of IDO | Quantification of apoptosis by flow cytometry | The day following surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04529421 -
Assocation Between In-person Instruction and COVID-19 Risk
|
||
Recruiting |
NCT04081792 -
Optimal Antibiotics for Operated Diabetic Foot Infections
|
N/A | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Recruiting |
NCT04674657 -
Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
|
||
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Recruiting |
NCT00342589 -
New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
|
||
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Completed |
NCT03296423 -
Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly
|
Phase 4 | |
Withdrawn |
NCT04217252 -
Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02905552 -
Myelodysplasic Syndromes and Risk Factors for Infection
|
N/A | |
Withdrawn |
NCT02904434 -
Gastrointestinal Implications of Voriconazole Exposure
|
||
Active, not recruiting |
NCT02768454 -
Antimicrobials Stewardship by Pharmacist
|
N/A | |
Completed |
NCT02219776 -
Decreasing Infection In Arthroscopic Shoulder Surgery
|
N/A | |
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Recruiting |
NCT02098226 -
Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts
|
N/A | |
Completed |
NCT01846832 -
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
|
Phase 3 | |
Terminated |
NCT01441206 -
Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants
|
Phase 1 | |
Completed |
NCT01434797 -
Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
|
||
Completed |
NCT01159834 -
Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)
|
N/A |